Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
By S. Hadziyannis, N. Tassopoulos, E. Heathcote, Ting Chang, G. Kitis, M. Rizzetto, P. Marcellin, Seng‐Gee Lim, Z. Goodman, M. Wulfsohn and 3 more. New England Journal of Medicine, 2003
1,030 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/155eaf33d4e800c9b8dbb89c038f9dd8cfdb7efb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
Citations in the corpus
- Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. (2005, background): “atitis B virus infection, renal failure rates appear low [183, 184].”
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. (2004, background): “To gain insight on the persistence of cccDNA and clearance mechanisms, we studied patients in different phases of the natural history of CH-B and a group of patients participating in a placebo-controlled trial of the recently approved nucleotide analog adefovir dipivoxil (ADV) 16,17 .”